| Identification | Back Directory | [Name]
6-Amino-2,3-dihydro-5-[(phenylmethylene)amino]-2-4(1H)-pyrimidineone | [CAS]
64232-83-3 | [Synonyms]
L189
L 189;L189
(E)-6-amino-5-(benzylideneamino)-2-mercaptopyrimidin-4-ol
6-Amino-2,3-dihydro-5-[(phenylmethylene)amino]-2-4(1H)-pyrimidineone
6-Amino-2,3-dihydro-5-[(phenylmethylene)amino]-2-thioxo-4(1H)-pyrimidinone
4(1H)-PyriMidinone, 6-aMino-2,3-dihydro-5-[(phenylMethylene)aMino]-2-thioxo- | [Molecular Formula]
C11H10N4OS | [MDL Number]
MFCD11556233 | [MOL File]
64232-83-3.mol | [Molecular Weight]
246.29 |
| Chemical Properties | Back Directory | [Melting point ]
250 °C (decomp) | [density ]
1.45±0.1 g/cm3(Predicted) | [storage temp. ]
Keep in dark place,Inert atmosphere,2-8°C | [solubility ]
≥62.5 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O | [form ]
solid | [pka]
8.16±0.60(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Description]
L189 is a competitive inhibitor of DNA ligases I, III, and IV (IC50s = 5, 9, and 5 μM, respectively). It blocks DNA binding (Ki = 5 μM for DNA ligase I), increasing the cytotoxicity of DNA-damaging agents, including ionizing radiation. L189 preferentially inhibits the interaction of the ligase with damaged DNA, inhibiting base excision repair and non-homologous end-joining. | [Uses]
L189 has been shown to inhibit DNA ligases I, III, and IV and may have potential use in the development of anticancer agents. | [storage]
Store at -20°C | [References]
[1]. xi chen, shijun zhong, xiao zhu, et al. rational design of human dna ligase inhibitors that target cellular dna replication and repair. cancer res., 2008, 68(9): 3169-3177.
[2]. mark r. taylor, john a. conrad, daniel wahl, et al. kinetic mechanism of human dna ligase i reveals magnesium-dependent changes in the rate-limiting step that compromise ligation efficiency. journal of biological chemistry, 2011, 286(26): 23054-23062.
[3]. christian jekimovs, emma bolderson, amila suraweera, et al. chemotherapeutic compounds targeting the dna double-strand break repair pathways: the good, the bad, and the promising. frontiers in oncology, 2014, 4: article 86. |
|
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|